Gene Therapy Company Reveals Promising Results From Huntington's Disease Clinical Trials

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company dedicated to developing transformative therapies for severe medical conditions, has recently shared promising interim data from its Phase I/II clinical trials of AMT-130 for Huntington’s disease. This update includes up to 24 months of follow-up data from 29 treated patients enrolled in these ongoing studies in the U.S. and Europe. $uniQure NV (QURE.US)$